MW073

MW073
Clinical data
Other namesMW-073
Drug classSerotonin 5-HT2B receptor antagonist
ATC code
  • None
Identifiers
  • 4-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-6-naphthalen-2-ylpyridazin-3-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H27N5
Molar mass361.493 g·mol−1
3D model (JSmol)
  • CC1=CC(=NN=C1NCCN2CCN(CC2)C)C3=CC4=CC=CC=C4C=C3
  • InChI=1S/C22H27N5/c1-17-15-21(20-8-7-18-5-3-4-6-19(18)16-20)24-25-22(17)23-9-10-27-13-11-26(2)12-14-27/h3-8,15-16H,9-14H2,1-2H3,(H,23,25)
  • Key:IBOOAZHRKKSRLF-UHFFFAOYSA-N

MW073 is a serotonin 5-HT2B receptor antagonist which is used in scientific research.[1][2][3][4][5] It is a highly selective antagonist of the serotonin 5-HT2B receptor.[3][2] The drug is orally active in animals and is said to have a favorable drug-like profile.[3][2] It produces antiaggressive effects without causing sedation or altering locomotor activity or anxiety in an animal model of Alzheimer's disease.[3][2] Similarly, it produces neuroprotective, neurorestorative, and pro-cognitive-like effects in such models.[3][2][5] MW073 was first described in the scientific literature by 2024.[4][2][3][5] There is interest in MW073 for the potential treatment of Alzheimer's disease and other conditions.[3][2]

See also

References

  1. ^ "Delving into the Latest Updates on MW073 with Synapse". Synapse. 9 May 2026. Retrieved 9 June 2026.
  2. ^ a b c d e f g Roy SM, Acquarone E, Argyrousi EK, Zhang H, Staniszewski A, Inoue A, et al. (2025). "Optimized 5-HT2b inhibitors for neuropsychiatric syndromes with cognitive dysfunction". Alzheimer's & Dementia. 11 (1) e70073. New York, N. Y. doi:10.1002/trc2.70073. PMC 11947739. PMID 40151398.
  3. ^ a b c d e f g Acquarone E, Roy SM, Staniszewski A, Watterson DM, Arancio O (February 2026). "The Highly Selective 5-HT2B Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse Model". Cells. 15 (3). doi:10.3390/cells15030273. PMC 12896383. PMID 41677635.
  4. ^ a b Acquarone E, Argyrousi EK, Arancio O, Watterson DM, Roy SM (2024). "The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction". Journal of Alzheimer's Disease. 98 (4): 1349–1360. doi:10.3233/JAD-240063. PMC 11091653. PMID 38578894.
  5. ^ a b c Roy S, Acquarone E, Ziarek JJ, Ottavio A, Watterson DM (2026). "MW073 Treatment Attenuates Synaptic Dysfunction, Cognition-Related Behavior Deficits, and Aggression in Alzheimer's Disease Models (Abstract ID: 273213)". The Journal of Pharmacology and Experimental Therapeutics. 393 (5) 104835. doi:10.1016/j.jpet.2026.104835.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.